|
Clinical outcomes and healthcare resource utilization (HCRU) in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) reinitiating erythropoiesis-stimulating agents (ESAs) following previous ESA treatment. |
|
|
Honoraria - Abbvie; Acceleron Pharma; Astex Pharmaceuticals; Bristol-Myers Squibb/Celgene; Curis; Genentech; Gilead Sciences; Novartis |
Consulting or Advisory Role - Acceleron Pharma; Astex Pharmaceuticals; Bristol-Myers Squibb |
Research Funding - Abbvie; Aprea Therapeutics; Astex Pharmaceuticals; Bristol-Myers Squibb; Curis; Genentech; Gilead Sciences; Novartis |
|
|
|
Stock and Other Ownership Interests - Syapse |
Research Funding - Bristol-Myers Squibb (Inst) |
|
|
Employment - Bristol-Myers Squibb/Celgene |
Consulting or Advisory Role - EMD Serono; Pfizer; Sandoz |
Speakers' Bureau - Bristol-Myers Squibb; Coherus Biosciences; Incyte |
|
|
|
|
Stock and Other Ownership Interests - Syapse; Sygnomics |
Consulting or Advisory Role - GenomiCare Biotechnology; Sygnomics |
Research Funding - Syapse |
Travel, Accommodations, Expenses - Syapse |
|
|
No Relationships to Disclose |
|
|
|
Research Funding - Bristol Myers Squibb Foundation (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Research Funding - Bristol Myers Squibb Foundation (Inst) |
|
|
Employment - McKesson; Syapse |
|
|
|
Research Funding - Bristol-Myers Squibb (Inst) |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Syapse |
Research Funding - Syapse |
|
|
Honoraria - Aplastic Anemia and MDS International Foundation; McGraw-Hill Education |
Consulting or Advisory Role - Abbvie/Genentech; Blueprint Medicines; Bristol Myers Squibb; EUSA Pharma; Novartis; OncLive; Paradigm |
Speakers' Bureau - EUSA Pharma |
Research Funding - BMS (formerly Celgene) (Inst); Jazz Pharmaceuticals (Inst); Novartis (Inst) |
Travel, Accommodations, Expenses - EUSA Pharma |